Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).
The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.
A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.
Eligibility criteria
Qualifiers
None
Disqualifiers
Participants unable to follow up at MD Anderson for routine clinical care
Inability or unwillingness to give informed consent
Relapsed disease or life expectancy less than 6 months at time of enrollment
Severe claustrophobia precluding MRI imaging
Trial design
Treatments tested in this trial
- 29-XeMRI imaging
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov